Blog

Gene Therapy Developer Tocagen Files for $86M IPO – Genetic Engineering & Biotechnology News (press release)


FierceBiotech

Gene Therapy Developer Tocagen Files for $86M IPO
Genetic Engineering & Biotechnology News (press release)
Tocagen, a gene therapy developer focused on treating brain cancer, will seek to raise $86 million through an initial public offering, according to an S-1 registration statement filed with the U.S. Securities and Exchange Commission. Tocagen's lead
Tocagen seeks $86M IPO to fund cancer gene therapy trialFierceBiotech


Tocagen readies IPOSeeking Alpha

all 4 news articles »

2017-03-10 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.